Several recently reported evidence-based phase 3 trials that focus on the role of cytotoxic chemotherapy have the potential to strongly influence the care of women with advanced epithelial ovarian cancer. Particular areas of interest include: (a) neoadjuvant chemotherapy; (b) chemotherapy of recurrent platinum-sensitive ovarian cancer; and (c) the relevance of paclitaxel scheduling in the prima...

BACKGROUND The treatment of patients with recurrent ovarian carcinoma after failure of first and second-line chemotherapy is still debated. Chemical agents used for third and fourth-line therapy usually yield poor results with severe toxic side effects. OBJECTIVE To summarize our experience with goserelin in the treatment of patients with recurrent ovarian cancer. METHODS From September 199...

BACKGROUND Ovarian cancer's prognosis remains dire after primary therapy. Recurrence rate is disappointingly high as 60% of women with epithelial ovarian cancer considered in remission will develop recurrent disease within 5 years. Special attention to undetected peritoneal metastasis during surgery is necessary as they are the main predictive factors of recurrences. Folate Receptor α (FRα) sho...

Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the platinum-resistant setting, and recently reported data reveal the superiority of the combination of PLD plus carboplatin, compared with the platinum drug plus paclitaxel, in delaying the time to disease progression in...

Most patients with ovarian cancer undergo surgery at some point during the course of their treatment. A primary operation may be undertaken for the purpose of confirming the diagnosis, staging, and debulking. Numerous publications have documented the importance of proper staging in ovarian cancer, which determines the treatment plan — including whether chemotherapy is indicated — and therefore ...

OBJECTIVE Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective. METHOD...

BACKGROUND The outcome and prognosis of ovarian cancer is highly variable. The objective of this study was to compare survival and clinicopathological prognostic factors with the expression levels of two matrix metalloproteinases (MMP) and fibronectin as tumor invasion and metastasis markers in ovarian cancer patients. MATERIALS AND METHODS Histologically-verified epithelial ovarian tumours f...

BACKGROUND AND OBJECTIVE Overexpression of YKL-40 has been detected in the sera from patients with various kinds of malignant tumors, including epithelial ovarian cancer. Moreover, YKL-40 expression is closely related to clinical phenotypes of some malignant tumors. This study was to investigate the expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. M...

Neoplasms of the ovary are the cause of more deaths than any other female cancer. Approximately 23% of all gynaecological cancer are of ovarian origin, but 47% of all deaths from cancer of the female genital tract are due to ovarian carcinoma. Combination systemic chemotherapy frequently produces startling remissions and yet the overall five year survival rate remains 25%, the lowest survival s...

BACKGROUND To evaluate the efficacy and safety of distearoylphosphatidylcholine pegylated liposomal doxorubicin (DPLD) combined with carboplatin for the treatment of platinum resistant or refractory epithelial ovarian cancer (EOC) or fallopian tube cancer. MATERIALS AND METHODS A retrospective analysis of women who received DPLD with carboplatin for recurrent EOC or fallopian tube cancer in K...